Literature DB >> 22852790

The PRIPS study: screening battery for subjects at risk for Parkinson's disease.

D Berg1, J Godau, K Seppi, S Behnke, I Liepelt-Scarfone, S Lerche, H Stockner, A Gaenslen, P Mahlknecht, H Huber, K Srulijes, J Klenk, K Fassbender, W Maetzler, W Poewe.   

Abstract

BACKGROUND AND
PURPOSE: Screening batteries to narrow down a target-at-risk population are essential for trials testing neuroprotective compounds aiming to delay or prevent onset of Parkinson's disease (PD).
METHODS: The PRIPS study focuses on early detection of incident PD in 1847 at baseline PD-free subjects, and assessed age, male gender, positive family history, hyposmia, subtle motor impairment and enlarged substantia nigra hyperechogenicity (SN+).
RESULTS: After 3 years follow-up 11 subjects had developed PD. In this analysis of the secondary outcome parameters, sensitivity and specificity of baseline markers for incident PD were calculated in 1352 subjects with complete datasets (10 PD patients). The best approach for prediction of incident PD comprised three steps: (i) prescreening for age, (ii) primary screening for positive family history and/or hyposmia, and (iii) secondary screening for SN+.
CONCLUSION: With this approach, one out of 16 positively screened participants developed PD compared to one out of 135 in the original cohort. This corresponds to a sensitivity of 80.0%, a specificity of 90.6% and a positive predictive value of 6.1%. These values are higher than for any single screening instrument but still too low for a feasible and cost-effective screening strategy which might require longer follow-up intervals and application of additional instruments.
© 2012 The Author(s) European Journal of Neurology © 2012 EFNS.

Entities:  

Mesh:

Year:  2012        PMID: 22852790     DOI: 10.1111/j.1468-1331.2012.03798.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  48 in total

Review 1.  Advances in Biomarker Research in Parkinson's Disease.

Authors:  Shyamal H Mehta; Charles H Adler
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

2.  Individual and joint prevalence of three nonmotor symptoms of PD in the US general population.

Authors:  Honglei Chen; Xuemei Huang; Xuguang Guo; Shyamal Peddada
Journal:  Mov Disord       Date:  2014-07-01       Impact factor: 10.338

3.  Clinical and neuroimaging correlates of progression of mild parkinsonian signs in community-dwelling older adults.

Authors:  Cameron Miller-Patterson; Jennifer Han; Kristine Yaffe; Andrea L Rosso; Lenore J Launer; Stephen B Kritchevsky; Robert M Boudreau; Caterina Rosano
Journal:  Parkinsonism Relat Disord       Date:  2020-05-22       Impact factor: 4.891

4.  Subjects at risk of Parkinson's disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study.

Authors:  Makoto Hattori; Takashi Tsuboi; Katsunori Yokoi; Yasuhiro Tanaka; Maki Sato; Keisuke Suzuki; Yutaka Arahata; Akihiro Hori; Motoshi Kawashima; Akihiro Hirakawa; Yukihiko Washimi; Hirohisa Watanabe; Masahisa Katsuno
Journal:  J Neurol       Date:  2020-02-07       Impact factor: 4.849

5.  Potential sex differences in nonmotor symptoms in early drug-naive Parkinson disease.

Authors:  Rui Liu; David M Umbach; Shyamal D Peddada; Zongli Xu; Alexander I Tröster; Xuemei Huang; Honglei Chen
Journal:  Neurology       Date:  2015-04-29       Impact factor: 9.910

6.  Relationship Between Poor Olfaction and Mortality Among Community-Dwelling Older Adults: A Cohort Study.

Authors:  Bojing Liu; Zhehui Luo; Jayant M Pinto; Eric J Shiroma; Gregory J Tranah; Karin Wirdefeldt; Fang Fang; Tamara B Harris; Honglei Chen
Journal:  Ann Intern Med       Date:  2019-04-30       Impact factor: 25.391

Review 7.  Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?

Authors:  Weidong Le; Jie Dong; Song Li; Amos D Korczyn
Journal:  Neurosci Bull       Date:  2017-09-02       Impact factor: 5.203

Review 8.  Laboratory assessments in the course of Parkinson's disease: a clinician's perspective.

Authors:  Thomas Müller; Horst Baas; Jan Kassubek; Peter Riederer; Peter Paul Urban; Christoph Schrader; Heinz Reichmann; Dirk Woitalla; Manfred Gerlach
Journal:  J Neural Transm (Vienna)       Date:  2015-11-14       Impact factor: 3.575

Review 9.  Is there a need to redefine Parkinson's disease?

Authors:  Philipp Mahlknecht; Werner Poewe
Journal:  J Neural Transm (Vienna)       Date:  2013-05-29       Impact factor: 3.575

10.  Risk factors and prodromal markers and the development of Parkinson's disease.

Authors:  Stefanie Lerche; Klaus Seppi; Stefanie Behnke; Inga Liepelt-Scarfone; Jana Godau; Philipp Mahlknecht; Alexandra Gaenslen; Kathrin Brockmann; Karin Srulijes; Heiko Huber; Isabel Wurster; Heike Stockner; Stefan Kiechl; Johann Willeit; Arno Gasperi; Klaus Fassbender; Werner Poewe; Daniela Berg
Journal:  J Neurol       Date:  2013-11-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.